Nat. Rev. Clin. Oncol. doi: /nrclinonc

Slides:

Advertisements

Similar presentations

KEYNOTE-021: Pembrolizumab + Ipilimumab Active in Previously Treated Advanced NSCLC CCO Independent Conference Highlights of the 2015 ASCO Annual Meeting*

Advertisements

Brian Boulmay, MD LSUHSC- New Orleans Section of Hematology & Oncology

Bladder Cancer: A New Era in Treatment

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Response after initial increase in total tumour burden

Figure 3 Response after appearance of a new lesion

Nat. Rev. Clin. Oncol. doi: /nrclinonc

State of the Art in HCC: Immune Checkpoint Modulation

Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.

Figure 2 Multiscale modelling in oncology

Figure 5 Schematic illustration of different clinical trial designs

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Optimizing the Treatment of Recurrent/Metastatic SCCHN

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Cardiol. doi: /nrcardio

Figure 3 Monitoring clonal evolution using liquid biopsies

Figure 1 Key time points in the discovery and development of imatinib for the treatment of chronic myeloid leukaemia (CML) and gastrointestinal stromal.

Figure 2 Three-step approach to the assessment and management

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Copy-number variations in multiple myeloma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Program Goals Introduction Case 1: A 44-Year-Old Woman.

Figure 1 Underreporting of treatment-related toxicities by physicians, relative to patients with either advanced-stage lung cancer, or early-stage breast.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Basics of Immunotherapy Potential Therapeutic Targets.

Figure 2 Therapeutic targeting of the PI3K/AKT/mTOR pathway

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Advanced Lung Cancers: What's on the Horizon?

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 4 Example of a patients with CUP

Figure 1 CAR-T-cell design

Figure 4 Effects of delaying cardioprotective medications after anthracycline administration Figure 4 | Effects of delaying cardioprotective medications.

Figure 4 Combination immunotherapeutic approaches with imatinib

Figure 1 Cost of one month of treatment with

Figure 2 The association between CD8+ T‑cell density of the tumour

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 3 Drug cycling with collateral sensitivity

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Differences between MC and AC

Figure 3 Possible modalities for reconciliation of patient's and physician's report of symptomatic treatment-associated toxicities Figure 3 | Possible.

chemotherapy for patients with MC versus those with AC

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 1 NIR fluorescence is more suitable for

Figure 3 Summary of overall survival by Kaplan–Meier

Figure 3 Clinical trial design in charged-particle therapy (CPT)

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Median monthly launch price of a new anticancer drug,

Figure 1 Translocations involved in multiple myeloma

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 2 Approaches to improve CAR-T-cell therapy

Figure 5 Palliative-care-referral patterns

Figure 5 Schematic overview of a clinical decision-support

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Figure 7 Overview of the methodological processes for

Figure 4 Radiogenomics analysis can reveal relationships

Figure 2 Radiomics in cardiology

Figure 1 Overview of the imaging biomarker roadmap

Moving Care Forward in Advanced Gastric Cancer

Figure 3 Determination of the primary site

Figure 1 Gene-expression quantification methods

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Presentation transcript:

Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2016.58 Figure 2 The most common adverse events in patients treated with ipilimumab, pembrolizumab, nivolumab, or ipilimumab plus nivolumab Figure 2 | The most common adverse events in patients treated with ipilimumab, pembrolizumab, nivolumab, or ipilimumab plus nivolumab. Incidence per 1,000 person-months. These incidences include data from the following studies: CA-184-002 (Ref. 16), KEYNOTE-001 (Ref. 30), KEYNOTE-001 (randomized cohorts31), KEYNOTE-002 (Ref. 32), KEYNOTE-006 (Ref. 33), CheckMate-037 (Ref. 100), CheckMate-066 (Ref. 29), CheckMate-067 (Ref. 45), and CheckMate-069 (Ref. 44). Boutros, C. et al. (2016) Safety profiles of anti-CTLA‑4 and anti‑PD‑1 antibodies alone and in combination Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2016.58